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Summary Data from the screening programme in British Columbia are used to test hypotheses about the
natural history of cervical cancer, especially about progression and regression of preclinical lesions (dysplasia
and carcinoma in situ). Three models are considered. A model without regression does not give an adequate fit
of the data (P<0.001), and results in an implausible estimate of 33 years for the mean duration of
pre-invasive lesions. A model with an equal regression rate at all ages still does not result in a good
reproduction of the data. A good fit is achieved for a model with different regression rates in lesions that
develop under and over age 34. Under age 34, 84% of the new lesions will regress spontaneously, with a 95%
confidence interval of 76-92% regression. Over age 34, we estimate that 40% of the new lesions will regress.
The average duration of dysplasia + CIS is 11.8 years, and the sensitivity of the Pap-smear is 80%. It is
concluded that a considerable proportion of pre-invasive lesions in young women do not progress. The
findings about progression and duration of pre-invasive lesions do not support the still prevailing tendency of
frequently making Pap smears in young women.
Regression of pre-invasive cervical cancer is still a controver-
sial issue. The possibility of regression, which may not occur
at the same rate at all ages, is important for decision making
about screening policies and about management of these
lesions. A high regression rate would mean that many screen-
detected lesions are diagnosed and treated unnecessarily. This
would influence the balance between favourable and adverse
effects of screening.
In the analysis of the screening data from the British
Columbia cohort study, a considerable amount of regression
was found. The regression is concentrated in lesions detected
at younger ages (Boyes et al., 1982). This finding was based
on a comparison of the estimated cumulative incidence of
pre-invasive lesions with the prevalence of these lesions and
with the cumulative incidence of clinically diagnosed invasive
cervical cancer. However, no explicit hypotheses about
regression were tested. A model based approach would allow
for using the details age-specific data from the cohort study
in testing the assumptions. Earlier modelling efforts, e.g. by
Coppleson and Brown (1975) also pointed at the existence of
regression, but used a combination of data from widely
different sources.
For breast cancer, Day and Walter (1984) proposed a
simplified model that can be used in analysing data from
screening programs. In this paper we propose a simplified
model for cervical cancer, and use the model to test hypo-
theses about regression against data from the screening pro-
gram in British Columbia.
A model for cervical cancer is more complicated than for
breast cancer, because of the long duration of pre-invasive
stages and the possibility of regression. The proposed model
contains the essentials of screening for cervical cancer: inci-
dence of pre-invasive lesions, duration, progression and pos-
sible regression of these lesions, and sensitivity of the Pap
smear.
Three hypotheses about regression of pre-invasive lesions
are tested: (A) no regression, (B) a constant rate ofregression
at all ages, and (C) different regression rates for lesions that
occur in young and middle-aged women, respectively.
Material and methods
The data used in testing the hypotheses are all derived from
the report of the British Columbia cohort study (Boyes et al.,
1982). This study analysed the records of the screening pro-
gram in British Columbia in the period 1949-1969, for two
cohorts of women, born in 1914-18 and 1929-33, respec-
tively. A full overview of the data is presented in Appendix
A, Table A-I.
The age-specific incidence of clinical cervical cancer is
based on data for the total female population between ages
20-24 and 60-64 in British Columbia in 1955-1957. Cervi-
cal cancer screening started already around 1950 in British
Columbia, but only on a very limited scale. The impact on
clinical incidence in the first years of screening has pre-
sumably been negligible. Thus, the incidence in 1955-57 is
considered to represent the situation without screening. We
converted the clinical incidence into an incidence rate for the
female population at risk of cervical cancer by correcting for
the cumulative hysterectomy rates recorded in the two cohort
study populations.
A distinct advantage of the data from British Columbia is
that age-specific rates are available over a broad age-range,
both for clinically diagnosed cancers and for screen-detected
lesions. The two cohorts together span the age-range 20-54
in the study period. In the overlapping age-group 35-39,
results from the younger cohort are used because of the
larger numbers in this group. It is assumed that the cross-
sectional clinical incidence data and the longitudinal screen-
ing data are comparable. Differences between these data sets
could be caused by cohort effects, but cohort differences were
not found in the cohort study (Boyes et al., 1982).
Regression is supposed to occur only in pre-invasive
lesions. The observed detection rates of pre-invasive lesions
(dysplasia and carcinoma in situ) of a first smear are included
in estimating and testing the assumptions about regression
(see Table A-I). In the results of the second and subsequent
smears, the pre-invasive and early invasive lesions are pooled,
because of the small numbers in the latter category. On basis
of the tables in the report of the cohort study, these results
are classified by age at midpoint between the first and second
smear, and by the time since the preceding Pap-smear.
The clinical incidence rates in the unscreened parts of the
cohorts are also used in testing the model. An important
reason for including these data in the analysis is that they
contain information about the difference in potential risk for
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cervical cancer between participants and non-participants in
screening.
The model
The model consists of five states: no cervical cancer; pre-
invasive cervical cancer; pre-clinical invasive cervical cancer;
screen-detected lesions; and clinical cervical cancer, see
Figure 1. Death from other causes and hysterectomies for
other reasons than cervical cancer are treated as independent
exogenous factors that have no influence on incidence rates
in the 'at risk' population or on screen-detection rates. Sur-
vival of screen-detected and clinical cervical cancer and death
from cervical cancer are not considered in the model since
they do not relate to the problem of regression.
The model is stochastic, i.e., the disease process is des-
cribed in probabilistic terms. The transitions between stages
are described by probabilities, and the dwelling time within
the stage pre-invasive cervical cancer is governed by a prob-
ability distribution.
The onset of pre-invasive screen-detectable stages corres-
ponding with dysplasia and carcinoma in situ is reflected in
the transition from no cervical cancer to pre-invasive cervical
cancer. This onset is assumed to be age-dependent and starts
at age ao. Women who participate in screening are assumed
to have a relative risk rr in comparison with the total popula-
tion.
From pre-invasive cervical cancer, the lesion may regress
spontaneously (i.e., return to no cervical cancer) or it may
progress into pre-clinical invasive cervical cancer. The pro-
portion of cases in which progression occurs is age-depen-
dent. The state pre-clinical invasive cervical cancer consists of
micro-invasive lesions and occult tumours. The duration in
this stage, i.e., the time between invasion and clinical diag-
nosis of cervical cancer, is assumed to be the same in all
women. All invasive lesions are assumed to be progressive.
This chain of probabilities will result in the (age-dependent)
clinical incidence rate.
The lesions in stages pre-invasive cervical cancer and pre-
clinical invasive cancer can be detected when a Pap smear is
made. The sensitivity of this screening test is sp for pre-
invasive and s, for invasive lesions, respectively. The detec-
tion rates for women who have a Pap smear will depend on
their age, on the rank of the smear, and on the time since the
preceding smear. The formulae for the clinical incidence rate
and the detection rates at first, second, and subsequent Pap-
smears are given in Appendix B.
In order to make the model more parsimonious, a number
of simplifications are made. First, both the onset rate of
pre-invasive lesions and the proportion of progressive lesions
are assumed to have two levels. Onset rate r, and proportion
progression p, apply to younger women (between ages ao and
a,), and levels r2 and P2 apply to women of age a, and older.
Second, the pre-invasive duration is described by a Weibull
probability distribution which has two parameters: mean
duration m and shape (or concentration parameter) b. The
Weibull distribution is a generalisation of the exponential
distribution. The additional concentration parameter allows
for changing the variance in the duration independently from
the mean, higher values indicating less variability.
Third, the duration ofthe preclinical invasive stage and the
sensitivity in this stage are assessed directly from the clinical
Figure 1 Schematic representation of the model.
incidence rates and detection rates of the first smear, see
Table A-III (Note that these detection rates are not included
in testing the model). The ratio of the two rates, shown in
the last column of the table, represents an estimate for the
product ofsensitivity and duration (approximately 3.6 years).
The sensitivity for invasive lesions was fixed at s,= 0.90, and
the duration was set at 4 years. A last simplification was used
in calculating the detection rates at second and subsequent
smears, see Appendix B for details.
In analysing the data, three models A, B and C are com-
pared. In model A, it is assumed that all pre-invasive cases
progress (p, =P2= 1.0). In models B and C only a certain
proportion of pre-invasive lesions will progress to invasive
cancer. In model B, this proportion is independent from age
(P =P2). In model C, the proportion of progressive lesions
differs between young and middle-aged women (p, =P2).
Model A has eight parameters: the relative risk (rr), the
ages and rates of the incidence of pre-invasive lesions (ao, a,,
r,, r2), the duration of pre-invasive lesions (m,b), and the
sensitivity of the Pap smear (sp), that are to estimated. By
including the progression parameters (p, and p2), model C
has ten parameters, while model B has only nine independent
parameters because the progression parameters are equal.
Estimationprocedure
The cohort study data on clinical incidence (eight age-cate-
gories after combining 20-24 and 25-29 because of very
small numbers), detection rates at the first smear (seven
categories), detection rates at the second and at subsequent
smears (2 x 4 x 3 categories), and the clinical incidence in
unscreened parts of the cohorts (six categories), are all
arranged into a single table (see Table A-I) with 45 entries.
For each set of parameter values, expected number of
cases according to the model are calculated. Both a Pearson
Chi-square test statistic for the goodness of fit and the
Likelihood are calculated from the expected and observed
numbers of cases. For each model, best-fitting parameter
estimates are obtained by maximisation of the likelihood.
The Likelihood-Ratio test is used to compare the models A,
B and C, and also in finding one- and two-dimension con-
fidence regions for the parameters. More specific details on
the estimation and testing procedures are given in Appendix
B.
Results
The best fitting parameter values for the three models (A, B
and C) are presented in Table I. The goodness-of-fit test for
the assumption that all pre-invasive lesions will progress to
become invasive cancers (model A) shows that it is not
possible to fit the data from British Columbia with this
assumption. Especially the results of second and subsequent
smears show large discrepancies between observed data and
the model (See Appendix A, Table A-I). The clinical inci-
dence and the detection rate ofthe first screen are fitted fairly
well. This obviously required quite surprising parameter
estimates: a very long average duration (33 years) of pre-
invasive lesions, coupled with an incidence rate of 1.3 x 10-3
between age 15 and 33 which is much higher than the clinical
incidence rate. After age 33, few pre-invasive lesions start
developing. Because of the low estimate (66%) for the sen-
sitivity of the Pap smear, the model gives too high detection
rates for smears made within a short interval after the
preceding smear. And the relatively low incidence rate of new
lesions results in much too low detection rates for smears
made after an interval of more than 3 years since the first or
second smear.
With a shape parameter of2.1 the variability in duration is
rather low, and only 24% of the pre-invasive lesions will
have a duration of less than 20 years. In other words:
although no explicit regression is assumed in model A, this
very long duration, with a considerable amount of (very)REGRESSION OF PRE-INVASIVE CERVICAL CANCER 561
Table I Parameter estimates forpre-invasive lesions ofcervical cancer, andgoodness of
fit of the three models
Model
A B C
No Regression Regression
regression constant age-dependent
Parameter
Incidence ofpre-invasive lesions
(rates x 103 women-years):
start at age ao: 15 15 18
change at age a,: 33 33 34
incidence rate r, (before age a,) 1.31 1.46 2.11
incidence rate r2 (after age a,) 0.16 0.54 1.06
relative risk rr ofparticipants 0.80 0.75 0.74
Duration and progression
of pre-invasive lesions:
mean duration m (years) 33.3 21.5 11.8
shape ofdistribution b 2.06 2.37 1.58
progression p, (before age a,) 1.00 0.47 0.16
progression P2 (after age a,) 1.00 0.47 0.60
Pap smear:
sensitivity sp 0.66 0.70 0.80
Goodness offit
P-value 0.0001 0.005 0.7
slow-progressing lesions, can be interpreted as a compen-
sating mechanism.
The assumption of an equal proportion regression at all
ages (model B) results in an estimate of 53% for the propor-
tion regression among pre-invasive lesions, see Table I. The
estimates for the onset after age 33, the mean duration of
pre-invasive lesions, and the sensitivity of the Pap smear
differ considerably from the case with no regression (model
A). Although model B gives a statistically significant
(P<0.0001) better fit than model A, the goodness of fit test
against the cohort study data still yields a P-value smaller
than 0.01. The same discrepancies with observed data found
in model A exist in model B; they are only less extreme.
The difference in log-likelihood between the model (A)
with no regression and the model (C) with age-dependent
regression indicates that a clearly significant (P<<0.0001)
improvement is brought about by adding age-dependent
regression. Moreover, model C gives a good fit ofthe observ-
ed data from British Columbia. Between age 18 and 34, the
incidence of pre-invasive lesions is high, and the estimated
proportion of regression among these lesions is 84%. The
proportion regression over age 34 is 40%. From all lesions
developing before age 65, an average of 62% is regressive.
Estimates for the other parameters show considerable differ-
ences compared to the case with no regression (model A, see
Table I). In women older than 34 years, there is a substanial
onset rate of new pre-invasive lesions. The estimates for the
duration ofpre-invasive lesions imply that the large majority
(85%) of the new progressive lesions will turn into invasive
lesions within 20 years. In combination with the higher sen-
sitivity (0.80) of the Pap smear, these changes lead to a
considerable improvement in the fit of the detection rate of
second and subsequent smears. The relative risk of partici-
pants is 0.74, indicating that unscreened women constitute a
high risk group.
For model (C), assumptions about average duration, sensi-
tivity, progression rate, and the shape have been varied to
find 95% confidence limits for these parameters, see Table II.
The mean duration of pre-invasive lesions is between 9.8 and
14.4 years. Mean durations of less than 9.8 years result in
clinical incidence rates becoming too high at older ages,
durations longer than 14.4 years will conversely result in too
high detection rates at older age. The range for the shape
parameter of the distribution means that the standard devia-
tion is between 5.9 and 12.1 years. The sensitivity of the Pap
smear for pre-invasive lesions is between 76% and 85%.
Other values will especially deteriorate the fits of detection
TableH Maximumlikelihoodestimates(MLE)andconfidenceranges
for the parameters of model C with age-dependent progression of
pre-invasive lesions
Parameter MLE Range
Incidence ofpre-invasive lesions
(rates x 103 women-years):
incidence rate, age <34 (ro) 2.11 1.75-2.83
incidence rate, age >34 (r,) 1.06 0.80-1.38
relative risk ofparticipants (rr) 0.74 0.62-0.85
Duration and progression of
pre-invasive lesions:
mean duration m (years) 11.8 9.8-14.5
shape ofdistribution (b) 1.58 0.92-2.12
progression, age <34 (p,) 0.16 0.08-0.24
progression, age >34 (p2) 0.60 0.42-0.88
Pap smear:
sensitivity (sp) 0.80 0.76-0.85
rates by interval at second and subsequent smears. The range
for progression in lesions starting before age 34 is 8-24%,
indicating that at most a quarter of these lesions will become
invasive. The lower bound is imposed by the clinical inci-
dence at young ages. The upper bound is imposed by an
overall tendency in all detection rates to become too low if
progression is over 30%. The range for the proportion pro-
gression over age 34 is rather wide (42-88%). Since 100%
progression is not included in the range, the model supports
the hypothesis that regression also occurs in lesions that
develop at higher ages.
We also considered alternative values for the ages (ao and
a,) at which the onset rate and progression change. The
confidence range for the age at which the onset starts is from
17 to 20 years, and the onset changes between ages 32 and
36. Outside both confidence ranges the fit deteriorates
rapidly. Note that in Table 18 in Boyes et al. (1982) already a
clear difference was shown between estimated incidence rates
of dysplasia before and after age 35.
Only slightly wider ranges are found when two-dimen-
sional confidence regions are considered, see Figure 2. For
example, even when the sensitivity would be known to be
77%, then the upper limit for progression is still only 27%.
From the figure it can be seen that variation in one para-
meter may be compensated by changing other parameters as
well. For example, a high proportion of regression is possible
when the onset rates are high, the mean duration short, and
the sensitivity high.562 G.J. VAN OORTMARSSEN & J.D.F. HABBEMA
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Figure 2 Two dimensional confidence regions for parameters of
pre-invasive cervical cancer, model C. 'Progression' is the propor-
tion of progressive lesions among new cases developing before
age 34. The points + denote the best-fitting combination of two
parameters. a, Progression and onset rate of pre-invasive lesions
before age 34. b, Progression and mean duration of pre-invasive
lesions. c, Progression and sensitivity of Pap smear in pre-
invasive stage.
Discussion
In the original analysis of the British Columbia cohort study,
it was concluded that regression is part of the natural history
of dysplasia and carcinoma in situ, and that regression is
more likely to occur at younger ages (Boyes et al., 1982). Our
analysis combines comprehensive data from this screening
project with a modelling approach in which the essential
aspects of the natural history ofcervical cancer and screening
are incorporated. The results show that it is possible to
obtain an adequate fit of the screening data set by assuming
that regression of pre-invasive lesions is age-dependent, with
a higher proportion of regressive lesions developing before
age 34. It is estimated that at least three quarters of these
lesions in young women and about one-third in middle-aged
women will regress spontaneously. We also analysed a model
in which 100% progression is assumed in middle-aged
women. This will give a statistically satisfactory fit of the
cohort study data. However, the fit improves significantly by
assuming that regression also occurs in lesions that develop
after age 34.
Assuming equal regression probabilities at all ages, or no
regression at all, will give rise to large discrepancies between
the model and the data from the cohort study.
Using Occam's razor in formulating the model has a clear
advantage, since it allows for testing of hypotheses in a
statistical framework. As a consequence, the resulting model
inevitably contains some biologically implausible aspects. For
example, age-related changes in the incidence and natural
history of pre-invasive lesions will occur gradually, and not
briskly at one specific age (34). Thus, the model should be
regarded as a filtered version of a more smoothly operating
process.
Both the sensitivity and the duration ofpre-invasive lesions
are assumed to be independent from age. Possibly, there
could be more fast growing lesions at increasing age, but
testing assumptions about age-dependent duration is hamper-
ed by the absence of screening data from age 54 onwards. It
is difficult to predict the consequences of such assumptions
for the estimated proportion regression, because of the con-
founding effects of other parameters that will also take
different values (as could be seen in Figure 2).
The average duration of regressive and progressive pre-
invasive lesions is assumed to be equal. A shorter duration
for regressive lesions would probably result in an even higher
proportion of (new) regressive lesions.
In model (C) with age-dependent regression, the confidence
interval for the concentration parameter governing the vari-
ability in the duration of pre-invasive lesions includes the
value b = 1.0 which represents an exponential distribution
(see Table II). This means that the current model is just not
significantly superior (0.05<P<0.1) to a further simplified
model with exponential dwelling time in the pre-invasive
stage. We also considered a log-normal distribution of the
duration of the pre-invasive state as an alternative for the
Weibull distribution. The resulting parameter estimates are
almost exactly the same as those for the Weibull distribution.
Only the mean and variation of the duration of the pre-
invasive state both give higher values, but it appears that
these difference are necessary to have about equal probabili-
ties for durations between 0 and 10 years. The goodness offit
does not improve for model C, and appears to be con-
siderably worse for the models with constant regression or no
regression (A and B).
For the preclinical invasive stage we assumed a fixed dura-
tion of 4 years and a sensitivity of the Pap smear of 90% in
order to arrive at the observed ratio between detection rate
and clinical incidence (see Table A-III). Other assumptions
about preclinical invasive cancers may as well fit the data.
For example, a different but still 'simplified' assumption is
that the duration of pre-invasive and preclinical invasive
stages are 100% correlated. This means that lesions with a
short dwelling time in the pre-invasive state will also have a
relatively short dwelling time in the preclinical invasive stage.
It appears that with this assumption, model C results in a
equally good fit of the observed data from the cohort study.
The values for most parameters are not very different from
those listed in Table I. Only for the concentration parameter
(b) a different value (2.0) is estimated, but this means that the
variability in the duration of the total pre-clinical period is
about the same for both assumptions.
There is general evidence that risk and participation to
cervical cancer screening are associated (Koopmanschap et
al., 1990b). The decision to include the relative risk para-
meter in the model was supported by the clearly higher
clinical incidence rates in the unscreened parts of the cohorts
in comparison with the clinical incidence in the total popula-
tion in the 'unscreened' situation in 1955-57. It was noted by
Boyes et al. (1982) that the acuracy of the clinical incidence
rates in the cohorts may suffer from problems in determining
the actual size of the unscreened 'at-risk' population. How-
ever, if these data are not used in the estimation procedure,
and the relative risk is given a fixed value assuming either no
difference in risk between participants and unscreened
women or a relative risk of 0.8 for participants, the resulting
parameter estimates are still within the confidence ranges for
the full model C as presented in Table II.
Since the period covered by the British Columbia cohort
study, there have been clear developments in diagnostic tech-
niques (colposcopy) and follow-up guidelines of early cyto-
logical abnormalities. In the early seventies, colposcopy was
introduced in British Columbia, hampering continued model-
based evaluation of the two study cohorts (Anderson et al.,
1988). Given the tendency towards treatment of very early
abnormalities, and the impossibility to discern regessive from
progressive lesions, it seem probable that the proportion of
regressive lesions among those treated after detection by
screening will become larger as a result of these develop-REGRESSION OF PRE-INVASIVE CERVICAL CANCER 563
ments.
Estimates for the proportion regression based on follow-up
of untreated cases of carcinoma in situ show great variations,
see Brinton (1986) for an overview. For carcinoma in situ
lesions, Kottmeier (1961) reported 71% progression to inva-
sive cancer after 12 years of follow-up. In contrast to this
figure is the 36% regression after 5 years of follow-up, as
reported by Kinlen and Spriggs (1976). They also found that
regression was confined to women aged less than 40 at the
time of the initial smear. These follow-up periods are short if
compared with the duration of preinvasive stages. The princi-
pal value of these studies is thus the support for the existence
of spontaneous regression.
Our estimate that a considerable proportion ofpre-invasive
lesions will progress to invasive stage does not prove a causal
relation between dysplasia and carcinoma in situ and invasive
cervical cancer. Evidence for such a relation is given by the
results of a combined analysis of data from major screening
programmes (IARC Working Group, 1986), indicating a
strong reduction in risk of invasive cervical cancer in the first
5-10 years after one or more negative Pap smears. We have
analysed the IARC data with model C, using the quanti-
fication given in Table I. Despite the apparent difference
between the long average duration of 11.8 years and the
relatively short duration of the protective effect reported by
the IARC study, we found that the model gives a good fit of
this reduction in risk (Van Oortmarssen & Habbema, 'Long
mean duration of pre-clinical stages of cervical cancer and
short protection by Pap smears: a reconciliation of two
epidemiological approaches', submitted for publication).
Among the models for evaluation ofcervical cancer screen-
ing (see Prorok (1986) for an overview), a number of other
'simplified' models for analysis of screening data have been
published. Coppleson and Brown (1975) use data on age
specific clinical incidence and detection rates of a first smear.
This is a much more limited data set than we used, and their
model shows some differences with our model. However, they
also found that the possibility of regression should be
included in the model in order to explain the observed data.
Albert (1981) tried to fit annual data concerning number of
cases with CIS, pre-clinical invasive, and clinical invasive
cancer in British Columbia. No distinction is made between
first and subsequent smears, and false negatives are neglect-
ed. In our opinion, too many important aspects (age-depen-
dencies, differences between first and subsequent smears) are
neglected in this model, and it is not suited for testing
assumptions about regression of CIS.
Brookmeyer and Day (1987) proposed an extension of the
model that Day and Walter developed for breast cancer
screening, which is similar to our extension. They analysed
data from a case-control study addressing the question of the
relative risk of invasive cancer for women who had a nega-
tive smear from. The data come from one of the screening
programmes involved in the IARC study (IARC working
group (1986)). Detection rates at successive smears are not
taken into account, and therefore the proportion of regres-
sion cannot be estimated from these data. The sensitivity of
the Pap smear and the mean duration of the pre-clinical stage
are estimated and have a large confidence region that
includes our estimates.
Gustafsson and Adami (1989) used a model that is similar
to ours, but includes mortality as an additional final stage.
Swedish population based incidence (CIS and invasive
cancer) and mortality rates are used to obtain estimates for
regression and duration of the preclinical stages. The
estimated mean duration of the pre-invasive stage is 13.3
years, which compares well with our estimate: Further simi-
larities are found for the variability of the duration (40% of
new lesions will become invasive within 10 years, compared
to 47% in our model) and the mean duration (3.9 years) of
pre-clinical invasive lesions. However, the proportion pro-
gressive lesions is estimated to be lower (12%) than in our
model, and is found to be independent from age, resulting in
a marked difference with our model at higher ages. This low
proportion might be due to the fact that in analysing of the
Swedish data, no distinction could be made between results
of first and subsequent smears, see van Oortmarssen and
Habbema (1990) and Adami and Gustafsson (1990).
Other models for cervical cancer screening are comprehen-
sive rather than simplified, and try to give a realistic descrip-
tion of the processes involved. Such models are less useful for
estimation of parameters or testing of hypotheses. Typically,
these models aim at evaluation of different screening policies
(Knox, 1973; Eddy, 1981).
We conclude that the present analysis gives evidence for
the existence of a considerable proportion of regression,
especially at young ages. The implications of this finding for
cervical screening policies can best be considered in a cost-
effectiveness framework. Such as analysis, based on this and
other model-based analyses of screening data has been car-
ried out for the present situation regarding the epidemiology
and early detection and treatment possibilities for cervical
cancer. The medical findings are reported in van Ballegooijen
et al. (1990), and the economic aspects in Koopmanschap et
al. (1990a). The results point out that frequent screening at
young ages gives rise to an unfavourable balance between
favourable and adverse effects. It is also inefficient when
comparisons of the cost-effectiveness ratio are made with
screening at higher ages.
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APPENDIX A
Table A-I Overview of the data from the British Columbia cohort
study (Boyes et al., 1982), and the fit between expected numbers for
models A, B, C and observed numbers
Observed data Expected number ofcases
Age Rate x 10-' Cases Model A Model B Model C
Table A-II Comparison ofmodel A, B and C
Models 2 log likelihood ratio (XI) P-value
A-B 14.2 (I d.f.) <0.0001
B-C 30.9 (I d.f.) <0.0001
A-C 45.1 (2d.f.) <0.0001
(a) Clinical incic
20-2
30-3
35-3
40-4
45-4
50-5
55-5
60-6
(b) Unscreened:
Clinical incidc
25-5
30-3
35-3
40-4
45-4!
50-5
(c) First smear
20-2
25-2!
30-3
35-3!
40-4
45-4!
50-5,
(d) Second smea
by age
25-2
30-3
35-34
40-4
45-4!
50-5,
(e) Third + smea
age
25-2!
30-3
35-3!
40-4
45-4!
50-5
Interv,
(f) Second
smear 11
(coh 2) 12-3'
36
(coh 1) <1 1
12-3'
36
(g) Third +
smear <11
(coh 2) 12-3'
36
(coh 1) <11
12-31
> 36
dence
'9 3.2
14 10.1
19 23.6
4 29.8
9 45.7
4 53.5
i9 53.6
4 55.5
ence
i9 6.8
4 22.7
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(a) Clinical incidence ofinvasive cervical cancer 1955-7. (b) Clinical
incidence in the unscreened part of the cohorts. (c) First smear:
pre-invasive cancer. (d) Second smearbyageatmidpoint. (e)Thirdand
subsequent smears by age at mid-point. (f) Second smear by interval
since first screening. (g) Third and subsequent smears by interval since
preceding smear.
Table A-Ill Comparison ofscreen-detection rates at first smear, and
clinical incidence ofinvasive cancers
Screen-detected
Clinical incidence invasive cancers
Rate ( x 10-5) Rate ( x 10-') Ratio
Age Cases (INC) Cases (PCI) PCI:INC
20-24 1 0.8 0 0 N.A.
25-29 8 5.6 2 17 3.0
30-34 15 9.9 23 68 6.9
35-39 36 22.7 18 97 4.3
40-44 40 27.4 16 110 4.0
45-49 49 40.2 35 146 3.6
50-54 43 45.5 11 105 2.3
Appendix B
The formulae of the model.
In this appendix, we will give the formulae that have been used in
calculating the expected incidence rates and detection rates as shown
in Table A.1, on basis of the ten parameters of the model: ao, a,, rl,
r2, rr, m, b, pl, P2, sp (see Table I).
Functionsjz) and F{z) are the probability density and distribution,
respectively, of the duration z of the pre-invasive stage. The Weibull
distribution for F(z) is characterised by two parameters, scale c and
shape b:
F(Z) = 1 -e-(Z1C (1)
The scale parameter c can be obtained from the mean m, since m = c
r(1 + 1/b), where r() is the Gamma function.
The probability density and distribtuion functions for the duration
y = z + q of the total preclinical state is denoted by g(y) and G(y),
respectively, where q is the duration of the preclinical invasive stage.
The two variants for the relation between F(z) and G(y) are:
1. Fixed duration q of the preclinical invasive stage:
G(y) = Ry-q), and g(y)=AY-q) for y>q, G(y) = 0 and g(y) = 0 otherwise.
2. 100% correlation between z and q. Here v = m7 is the
average proportion of the preclinical duration in the pre-invasive
stage:
G(y) =1Rv.y), and g(y) = v.(v.y) for all y>0.
The clinical incidence I(a) at age a is derived from the onset rate
R(a-y), the proportion of progressive lesions p(a-y) and the distribu-
tion g(y) ofthe total duration y = z + q ofthe two pre-clinical stages:
a-ao
I(a)= f g(y)p(a-y)R(a-y)dy (2)
0
The clinical incidence applies to the total female population at risk,
which by definition has a relative risk equal to 1.0. For known values
of the relative risk rr of the screened population, the relative risk of
the unscreened population ru(a) is age-dependent via the fraction
screened x(a):
ru(a) = I-x(a).rr (3)
The incidence in the unscreened part of the cohorts is ru(a).I(a) and
can be derived from expression (2) and (3).
For convenience, we introduce N(a), the rate at which cases leave the
pre-invasive stage:
a-ao
N(a) = Iftz)R(a-z)dz
0 (4)
Now the detection rate of pre-invasive lesions at a first screening at
age a is:
a
Pp(a) = rrsp J (R(x) - N(x))dx (5)
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And the detection rate of invasive pre-clinical lesions:
a
P(a) = rrs, f (N(x) - I(x))dx (6)
0
The detection rate ofpre-clinical lesions for a second smear at age u2
depends on the age u, at which the first smear was made.
u
S(u1,u2) = rr R(a)[sp{1-F(u2-a)) +
a s1p(a)F(u2-a)-G(u2-a))] (1-sp)a da (7)
The notation (1-_Sp)a<u1 is used to indicate that the false negative
rate at the first screening should be taken into account only in cases
where the onset occurred before age u,.
For the detection rates of second and later smears, a further
simplifying assumption was made to reduce numerical complexity:
the fast negative rate at the subsequent smear(s) is assumed to be
1.0-sp for all screen-detectable lesions. Thus, the expression for the
false negative rate is an approximation, neglecting the lower false
negative rate 1.0-se in cases who are in stage preclinical invasive
already at age u2. This will result in a slight exaggeration of the
detection rate, since lesions that are in stage pre-clinical invasive
cervical cancer at preceding smears would have a false negative rate
of u2.
The detection rate at a third screen at age u3 depends on the ages
u, and u2 of the preceding smears:
U,
T(u,,u2,u3)= f rrR(aXI-S)2[Sp(U,_a)} +sp(aX{Fua)_G(u3-a))]da
aO
rrR(aXl-sp)[sp{l-I-(u3--a))+s,p(aXF(u3-a) - G(U3-a))]da
U' u,
+ J rrR(a)[sp{l-F(Iu3-a))+sp(aXF(u3-a) - G(u3-a))]da (8)
U2
The simplifications in R(a) and p(a) are:
rI ao<a<a,
R(a) = { r2 a>al
r Pi ao<a<al p(a) =(P2 a>a,
Expressions (2), (5), (7) and (8) can now be simplified considerably.
The resulting expressions are used to calculate expected rates for a
given set of parameter values. The clinical incidence I(a) and the
detection rate of a first smear are calculated for 1-year age-groups
and then aggregated to the classes used in the testing procedure. The
detection rates S(uj,u2) of a second smear are calculated for a matrix
of 'ages at mid-point of the interval' and intervals. The same method
is used for detection rates T(u,u2,u3) of third and subsequent smears,
assuming that the interval between the first and second smear is 1, 2,
3 or 5 years with probabilities 0.40, 0.30, 0.15 and 0.15, respectively
(based on women years in the published tables for the second smear).
These rates are also aggregated, after dividing the rates by the lengh
of the interval to obtain rates that have women-years as denomin-
ator. Expected numbers of cases are obtained by multiplying expect-
ed rates and observed denominators (women-years or number
screened).
The log-likelihood is based on the assumption that the observed
cases are a realisation of a Poisson-distribution with mean = expect-
ed number of cases. The likelihood is maximised using a downhill
simplex multidimensional optimisation routine (Press et al., 1988).
The total number of classes is 45, the number of degrees of freedom
for the Pearson Chi-Square test for the goodness of fit of the model
is 41 minus the number of free parameters that were varied in
deriving the maximum likelihood estimates. The number of degrees
of freedom equals the number of categories minus 4, since in each
cohort both expected and observed sum of cases detected with the
second smear and with subsequent smears is the same for the two
subclassifications (by age and by interval since first smear), as can be
seen in Table A-I. The deviance, i.e. the likelihood ratio test statistic
for comparing a model with the complete model, is also inspected in
assessing the goodness of fit.
Comparisons between models are based on the Likelihood-ratio
test. Also, 95% confidence regions for one and for two parameters
are obtained by inverting the Likelihood-ratio test, i.e., by searching
for parameter values for which the lbg likelihood is 3.84 . 2 respec-
tively 5.99 *. 2 lower than the log-likelihood of the optimal model.
One- and two-dimensional confidence regions (Table II, Figure 2) are
computed by repeatedly applying the downhill simplex optimisation
routine in combination with a root-finding algorithm.
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